DHT in Women: Normal Levels, High DHT Symptoms, Age-Specific Ranges, and What a Female DHT Test Means

WHAT IS DHT IN WOMEN?

Dihydrotestosterone (DHT) is a steroid hormone classified as an androgen — a group of hormones that regulate traits typically associated with male development. While DHT plays a central role in male physiology, it is also present in females, where it is produced in small amounts.

In women, DHT is made when the enzyme 5-alpha-reductase converts testosterone into DHT, primarily in:

• The ovaries
• The skin and hair follicles
• The liver and adrenal glands
• Other peripheral tissues

DHT binds the androgen receptor with substantially greater affinity than testosterone and has greater androgenic potency in target tissues. Unlike testosterone, DHT cannot be converted into estrogen — it acts as a "pure" androgen with highly localized effects in the tissues where it is produced.

Does DHT serve a function in women? At normal levels, DHT contributes modestly to pubic and body hair development during puberty. It does not appear to be essential for female reproductive function, fertility, or menstrual cycling. Problems arise when DHT levels rise above the normal range, where excess androgen activity produces androgenic symptoms.

NORMAL DHT LEVELS IN FEMALES

Reference ranges for DHT in women vary by laboratory, assay method, and age. The LC/MS/MS (liquid chromatography-tandem mass spectrometry) method is the most accurate and is now standard at major reference laboratories.

General adult female reference range:

Important: Always interpret your result using the reference range printed on your own lab report, as ranges vary by lab and analyzer.

Does "normal" change with age? Yes. DHT levels in females decline gradually across the lifespan, particularly after menopause when overall androgen production falls significantly.

Note on lab-specific ranges: Reference intervals for female DHT vary by laboratory, assay methodology, age, and menopausal status. Always interpret your result using the reference range provided on your specific lab report rather than relying on published approximations, which may not reflect current assay versions at your laboratory. If your result is borderline or flagged, confirm the reference interval with your ordering clinician before drawing conclusions.

WHAT DOES MY DHT RESULT MEAN? VALUE LOOKUP TABLE

If you have a specific DHT result and want to know what it means for a woman, use this table. Values are in ng/dL — the most common reporting unit in the US. To convert from pg/mL, divide by 10 (e.g., 180 pg/mL = 18 ng/dL).

Important: Reference ranges vary between laboratories. If your lab's printed reference range differs from the table above, use your lab's range as the primary reference. A result slightly above one lab's range may be within another lab's range.

Lab-specific context: Reference ranges vary between laboratories and assay versions. Always use the reference range printed on your own lab report as the primary guide. If your result is borderline, confirm interpretation with your clinician.

Specific value interpretation examples:

DHT LEVELS BY AGE IN FEMALES

DHT levels in females follow a predictable pattern across the lifespan driven by total androgen production:

Childhood: DHT is very low or undetectable before puberty. Adrenarche — the onset of adrenal androgen production around age 6–8 — leads to the first small increase in DHT and explains the appearance of pubic hair in early puberty.

Reproductive years (approximately 18–45): DHT is at its highest in adult females during the reproductive years. Levels may fluctuate slightly across the menstrual cycle but generally remain within the 40–220 pg/mL range. Elevations during this period are most commonly associated with PCOS, CAH, or other androgen excess conditions.

Perimenopause (approximately 45–55): Ovarian testosterone production begins to decline, and consequently DHT levels fall. Women in perimenopause may see values drift toward the lower end of the adult reference range.

Postmenopause: After menopause, ovarian production of androgens drops substantially. DHT levels in postmenopausal women are generally lower than in premenopausal women, though adrenal androgen production continues at reduced levels. Postmenopausal women with elevated DHT warrant evaluation for adrenal sources or exogenous androgen exposure.

SYMPTOMS OF HIGH DHT IN WOMEN

Elevated DHT in females produces androgenic (male-pattern) effects primarily in androgen-sensitive tissues — the skin, hair follicles, and sebaceous glands. The most commonly reported symptoms are:

An important distinction: These symptoms are caused by androgen excess generally — elevated testosterone often accompanies high DHT since DHT is produced from testosterone. A complete androgen panel (total testosterone, free testosterone, DHEA-S, androstenedione, DHT) gives a more complete picture than DHT alone.

The PCOS-DHT connection in detail: PCOS is the most common endocrine disorder in women of reproductive age, affecting approximately 8–13% of women globally. Elevated androgens — including DHT — are a core feature, present in 60–80% of PCOS cases. The typical PCOS androgen profile includes:

• Elevated total testosterone
• Elevated free testosterone (often with low SHBG)
• Elevated DHT
• Elevated androstenedione
• Elevated AMH
• Elevated LH:FSH ratio (often > 2:1)
• Insulin resistance in 50–70% of cases

How insulin resistance drives DHT elevation: Elevated insulin directly stimulates ovarian theca cells to produce more testosterone. More testosterone → more 5-alpha-reductase conversion → more DHT → more androgenic symptoms. This is why weight loss and insulin sensitization (including metformin) can reduce androgen levels and DHT in women with PCOS and insulin resistance:

Hyperinsulinemia → Theca cell stimulation → Excess testosterone production → Increased DHT → Hirsutism, acne, hair loss

Hair loss pattern interpretation: Not all hair loss in women is DHT-driven. The pattern of hair loss can help differentiate causes:

DHT-driven female pattern hair loss specifically affects the crown and produces a characteristic widening part line while the frontal hairline is often preserved — distinguishing it from male pattern baldness and from other causes of hair loss.

WHAT CAUSES HIGH DHT IN WOMEN?

The PCOS-DHT connection: PCOS is the most common endocrine disorder in women of reproductive age, affecting approximately 8–13% of women globally. Elevated androgens — including DHT — are a core feature, present in 60–80% of PCOS cases. DHT contributes directly to hirsutism and female pattern hair loss in PCOS.

DHT VS TESTOSTERONE IN WOMEN — WHAT'S THE DIFFERENCE?

DHT and testosterone are both androgens, but they behave differently in the body. Understanding the distinction helps interpret results when one is elevated and the other is not.

CAN YOU HAVE NORMAL TESTOSTERONE BUT HIGH DHT?

Yes — and this is clinically important. Some women with female pattern hair loss, hirsutism, or persistent acne have normal serum testosterone levels but elevated DHT or elevated local DHT activity in androgen-sensitive tissues.

How this happens:

Normal serum testosterone → Increased 5-alpha-reductase activity in skin and hair follicles → Increased local DHT production → Androgenic effects in tissue (hair loss, acne, hirsutism) → Normal testosterone blood test result

This pattern is called idiopathic hirsutism when serum androgens are normal but androgenic symptoms are present. It reflects increased local conversion efficiency rather than excess androgen production. In these women, serum DHT may be mildly elevated or at the high-normal end of the range even when testosterone is normal.

Clinical implication: A normal testosterone result does not rule out androgen-driven hair loss or hirsutism. Measuring DHT specifically — and evaluating free testosterone alongside SHBG — provides a more complete picture of androgenic activity.

TESTOSTERONE AND DHT PATTERN INTERPRETATION

When both testosterone and DHT are measured, the combination provides more diagnostic information than either alone:

Note: Free testosterone and SHBG provide important additional context. Low SHBG (common in insulin resistance and PCOS) increases free testosterone and therefore DHT production even when total testosterone appears normal.

THE DHT TEST FOR FEMALES — HOW IS IT DONE?

How is DHT measured? DHT is measured from a blood draw (serum or plasma). The preferred method at major reference laboratories is liquid chromatography-tandem mass spectrometry (LC/MS/MS), which is more accurate than older immunoassay methods, particularly at the low concentrations found in women.

When is DHT testing ordered for women?

Is DHT tested alone or with other hormones? Rarely alone. DHT is almost always ordered as part of a broader androgen panel that typically includes total testosterone, free testosterone, DHEA-S, androstenedione, LH, FSH, and sometimes prolactin and 17-hydroxyprogesterone depending on the clinical question.

What time of day and cycle day matters? Androgens including DHT are generally highest in the morning. For premenopausal women, testing is typically done in the early follicular phase (days 2–5 of the menstrual cycle) to standardize results, though for routine androgen excess evaluation the cycle day is less critical than for other hormones.

Specimen type: Serum (preferred) or plasma. LC/MS/MS method. No special preparation required though fasting is sometimes requested by individual labs.

Why serum DHT doesn't always reflect tissue DHT:

An important clinical nuance: serum DHT measures circulating blood levels, but many of DHT's effects occur locally in tissues — particularly in skin and hair follicles — where DHT is produced and acts without entering the bloodstream in significant quantities. This means:

• Some women with significant hirsutism, acne, or androgenic alopecia have normal serum DHT because the excess DHT is acting locally in the hair follicles and skin
• Serum DHT is a useful marker of systemic androgen excess but does not capture local tissue DHT activity
• A normal serum DHT result does not rule out androgen-driven hair loss or skin symptoms in all women

Testing limitations to be aware of:

• Do not measure DHT while taking high-dose biotin supplements (biotin can interfere with certain immunoassay-based hormone tests; less relevant with LC/MS/MS but worth noting)
• Avoid testing during acute illness, which can transiently alter androgen levels
• Women recently starting or stopping oral contraceptives, anti-androgens, or androgen therapy should allow 4–8 weeks after the change before testing for a reliable baseline
• Morning collection is preferred as androgens show mild diurnal variation, peaking in the morning

When should DHT NOT be tested — or results interpreted with caution?

DHT BLOCKERS FOR WOMEN — WHAT ARE THEY AND DO THEY WORK?

DHT blockers are agents that reduce DHT's effects either by blocking its production (5-alpha-reductase inhibitors) or blocking its binding to androgen receptors (anti-androgens). In women with symptoms of androgen excess, they are used to treat hirsutism, acne, and female pattern hair loss.

Prescription DHT blockers used in women:

Natural DHT blockers for women: Several supplements and foods are promoted as natural DHT blockers. The evidence for most is limited, but some have modest supporting data:

• Saw palmetto — contains fatty acids that may inhibit 5-alpha-reductase; limited RCT evidence in women
• Pumpkin seed oil — mild 5-alpha-reductase inhibitory activity in some studies
• Spearmint tea — anti-androgenic effects shown in small studies in women with PCOS
• Zinc — may reduce 5-alpha-reductase activity; commonly included in hair loss supplements
• Green tea (EGCG) — mild androgen receptor blocking activity in vitro

None of these natural options have the clinical evidence base of prescription anti-androgens. They may be appropriate as adjuncts but should not replace medical evaluation and treatment for significant androgen excess.

Side effects of DHT blockers in women: Spironolactone can cause irregular bleeding, breast tenderness, and elevated potassium. Finasteride and dutasteride are teratogenic and must be avoided in pregnancy. Women on anti-androgens should always be under medical supervision.

LOW DHT IN WOMEN — WHEN DOES IT MATTER?

Low DHT in women is generally not a primary clinical concern because DHT does not play an essential role in female reproductive function. However, low DHT can occur as part of broader androgen deficiency and may be associated with:

• Reduced libido (when part of overall low androgen levels)
• Reduced pubic and body hair
• Lower sebum production and drier skin
• Fatigue (when part of broader androgen deficiency syndrome)

Most common causes of low DHT in women:

• Low total testosterone (primary source of DHT is reduced)
• Hypopituitarism (reduced LH/FSH drive to ovarian androgen production)
• Premature ovarian insufficiency / early menopause
• Adrenal insufficiency
• Use of oral contraceptives (suppress ovarian androgen production)
• 5-alpha-reductase inhibitors (finasteride, dutasteride)
• Chronic illness or malnutrition

Low DHT in women is almost never treated directly. Management focuses on the underlying cause of androgen deficiency rather than DHT replacement specifically.

DHT IN PREGNANCY

DHT testing is not routinely performed or interpreted during pregnancy. Androgen physiology changes significantly during pregnancy:

• The placenta produces large amounts of steroids that alter normal hormone patterns
• Reference ranges established for non-pregnant women do not apply
• Some elevation in androgens during pregnancy is physiologically normal and does not indicate pathology
• Androgen-related symptoms that develop during pregnancy warrant evaluation but interpreted differently than in non-pregnant women

If you received a DHT result during pregnancy, discuss interpretation with your obstetrician or endocrinologist rather than relying on standard female reference ranges.

DHT ACROSS THE LIFESPAN — MENOPAUSE AND BEYOND

Postmenopausal women with elevated DHT warrant evaluation — elevated androgens after menopause are less common and may indicate adrenal pathology, androgen-secreting tumor, or exogenous androgen exposure.

SHOULD WOMEN LOWER THEIR DHT?

Not always. The decision to treat elevated DHT depends entirely on whether it is causing symptoms and whether the underlying cause has been identified.

DHT reduction is generally appropriate when:

• DHT is above the reference range AND symptoms are present (hirsutism, androgenic alopecia, persistent acne)
• PCOS is confirmed with androgen excess features
• Female pattern hair loss is progressing
• Quality of life is affected by androgenic symptoms

DHT reduction is generally NOT indicated when:

• DHT is within the normal reference range, even at the high-normal end
• There are no androgenic symptoms
• The elevation is mild and isolated without other abnormalities

Treating a normal DHT level — or treating a mild elevation without symptoms — is not evidence-based and may have side effects without clinical benefit.

HOW MEDICATIONS AFFECT DHT IN WOMEN

Many commonly used medications alter DHT levels. If you are on any of the following, your DHT result should be interpreted in that context:

HOW DHT FITS INTO THE ANDROGEN WORKUP

DHT is rarely the first test ordered when androgen excess is suspected. It sits within a broader diagnostic sequence that clinicians use to identify the source and severity of androgen excess in women:

Typical androgen workup sequence for women with suspected androgen excess:

Where results lead:

• High testosterone + high DHT + high LH:FSH + insulin resistance → PCOS most likely
• High DHEA-S + normal testosterone → Adrenal source (CAH or adrenal tumor)
• Normal androgens but symptoms present + high 5-alpha-reductase activity implied → Idiopathic hirsutism
• Very high testosterone (> 200 ng/dL) or very high DHEA-S → Androgen-secreting tumor — urgent evaluation
• Low androgens across the board → Androgen deficiency; evaluate pituitary and ovarian function

WHEN SHOULD ELEVATED DHT PROMPT URGENT EVALUATION?

Most elevated DHT results in women reflect PCOS or idiopathic hirsutism and are not emergencies. However, certain features warrant faster or more specialized evaluation:

Gradual-onset hirsutism or acne developing over years in a woman of reproductive age is the typical benign presentation of PCOS and does not require urgent evaluation. Rapid virilization, very high androgen levels, or postmenopausal onset warrant prompt referral to endocrinology.